Related Experiment Videos
Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG,
1Institute of Pathology, University of Cologne, Joseph-Stelzmannstrasse 9, 50924 Cologne, Germany. j.thiele@uni-koeln.de
Insights
The WHO classification, incorporating histopathology, more accurately diagnoses essential thrombocythemia (ET) compared to PVSG criteria. This leads to better prognosis assessment for ET and initial myelofibrosis patients.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Chronic myeloproliferative disorders require precise classification for accurate prognostication.
- Distinguishing essential thrombocythemia (ET) from early myelofibrosis (IMF) is clinically significant.
- Previous diagnostic criteria for ET may lead to misclassification.
Purpose of the Study:
- To compare the diagnostic accuracy of the Polycythemia Vera Study Group (PVSG) criteria versus the World Health Organization (WHO) classification for essential thrombocythemia.
- To evaluate the impact of diagnostic criteria on patient prognosis and survival outcomes.
Main Methods:
- A multicenter observational study involving 839 adult patients with chronic myeloproliferative disorders and high platelet counts.
- Comparison of PVSG diagnostic criteria with WHO classification, emphasizing histopathology.
- Follow-up examinations with sequential bone marrow biopsies in a subset of patients.
Main Results:
- WHO criteria, including histopathology, reclassified 321/483 (66.5%) PVSG-diagnosed ET patients to initial or early chronic idiopathic myelofibrosis (IMF).
- True ET patients showed minimal progression to fibrosis (2/49), while initial/early IMF patients frequently progressed (45/91).
- WHO criteria resulted in a significantly better survival estimate for ET patients (8.9% vs. 16.5% life expectancy loss).
Conclusions:
- The WHO classification provides a more accurate diagnosis of essential thrombocythemia by incorporating histopathology.
- Accurate differentiation between ET and early IMF is crucial for correct prognostic assessment and patient management.
- Adoption of WHO criteria is recommended for improved classification and survival prediction in myeloproliferative neoplasms.
Abstract:
A multicenter observational study was performed on 839 adult patients with a chronic myeloproliferative disorder and a platelet count in excess of 600 x 10(9)/l to compare the updated criteria of the Polycythemia Vera Study Group (PVSG) with the recently published WHO classification. Essential thrombocythemia (ET) was diagnosed in 483 patients according to the PVSG; however, when considering histopathology as a major diagnostic feature of the WHO criteria, (true) ET could be established in only 162 patients. The remaining cases were found to represent either initially prefibrotic (184 patients) or early fibrotic (137 patients) chronic idiopathic myelofibrosis (IMF). On the other hand, both classification systems enabled a clear-cut distinction of patients showing overt IMF and polycythemia vera. Follow-up examinations in 140 patients with ET according to the PVSG criteria included also sequential bone marrow biopsies (interval: 38+/-30 months). A transition into mild reticulin fibrosis occurred in only 2 of 49 patients with (true) ET in contrast to 45 of 91 patients with initial and early IMF where a progression into overt myelofibrosis was encountered. Survival patterns for ET displayed significant differences because according to the PVSG a 16.5% disease-specific loss of life expectancy was calculable compared to a value of only 8.9% when following the WHO criteria. Contrasting this finding, initial and early IMF mimicking ET was characteriZed by a reduction of life expectancy ranging between 21.6% and 32.3 %. In conclusion, a more accurate classification of ET is warranted by regarding the WHO criteria that include histopathology as a major feature for diagnosis.